Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 10/20 | 0.86 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.66 |
| ▸ | CDK2 | P24941 | 3/20 | 0.66 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.66 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20392483 | 0.99 | GLS (0.84) | GLSRECQLKMT2AMEN1ALDH1A1 | |
| SCHEMBL16887444 | 0.95 | GLS (0.90) | GLSRECQLKMT2AMEN1ALDH1A1 | |
| SCHEMBL15724974 | 0.93 | GLS (1.00) | GLSRECQLKMT2AMEN1ALDH1A1 | |
| SCHEMBL15724979 | 0.93 | GLS (1.00) | GLSRECQLKMT2AMEN1ALDH1A1 | |
| SCHEMBL15725006 | 0.93 | GLS (1.00) | GLSRECQLKMT2AMEN1ALDH1A1 | |
| SCHEMBL17172576 | 0.93 | GLS (1.00) | GLSRECQLKMT2AMEN1ALDH1A1 | |
| SCHEMBL15724980 | 0.93 | GLS (1.00) | GLSRECQLKMT2AMEN1ALDH1A1 | |
| SCHEMBL15724986 | 0.90 | GLS (1.00) | GLSRECQLKMT2APKMSMN1; SMN2 | |
| SCHEMBL15724994 | 0.90 | GLS (1.00) | GLSRECQLKMT2APKMSMN1; SMN2 | |
| SCHEMBL15724989 | 0.90 | GLS (1.00) | GLSRECQLKMT2APKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676471-B2 | Cycloalkyl-linked diheterocycle derivatives | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3556757-A1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | Pfizer Inc (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190270737-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270737-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 | GLS 550/4885RECQL 564/4885KMT2A 3638/4885 |
| US-10676471-B2 | Cycloalkyl-linked diheterocycle derivatives | CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 | GLS 550/4885RECQL 564/4885KMT2A 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.